Exclusion criteria
squamous-cell skin cancer, tumor, infectious, interstitial pneumonia, uveitis, asthma, autoimmune disease, trauma, death, Allergy, vasculitis, psoriasis, enteritis, tumour, interstitial lung disease, hypothyroidism, substance abuse, diabetes, autoimmune hepatitis, supraventricular or ventricular arrhythmias, infection, nephritis, malignancies, immune-related pulmonary toxicity, heart failure, skin diseases, cardiac symptoms, pneumonia, cancers, active pulmonary tuberculosis, idiopathic pneumonia, bacteremia, alcohol abuse, alopecia
TUMOR, RECURRENCE, INTERSTITIAL PNEUMONIA, HYPOPHYSITIS, UNSTABLE ANGINA, UVEITIS, ASTHMA, CARCINOMA IN SITU, INACTIVE PULMONARY TUBERCULOSIS, AUTOIMMUNE DISEASE, CHILDHOOD ASTHMA, PULMONARY FIBROSIS, ALLERGY, VASCULITIS, PSORIASIS, ENTERITIS, TUMOUR, INTERSTITIAL LUNG DISEASE, HYPOTHYROIDISM, DISEASES, DIABETES, AUTOIMMUNE HEPATITIS, SEVERE INFECTION, HYPERTHYROIDISM, INFECTION, ORGANIZED PNEUMONIA, NEPHRITIS, HEPATITIS C, MALIGNANCIES, HEART FAILURE, SKIN DISEASES, COMPLICATIONS, VIRUS, MYOCARDIAL INFARCTION, PNEUMONIA, CANCERS, METASTASIS, PULMONARY INFLAMMATION, PNEUMOCONIOSIS, LEUKOPLAKIA, LYMPH NODE METASTASIS, ALOPECIA, BRONCHIOLITIS OBLITERANS

Unresectable factors, including those who are unresectable for tumor reasons or have surgical contraindications, or who refuse surgery.Patients with supraclavicular lymph node metastasis.Poor nutritional status, BMI < 18.5 kg/m2; patients could continue to be considered for enrollment if corrected with symptomatic nutritional support before enrollment and after assessment by the principal investigator.Allergy to any drugs.Have received or are receiving any of the following treatments; (a) any radiotherapy, chemotherapy, or other anti-neoplastic drugs directed at the tumour; (b) treatment with an immuno-suppressive drug or systemic hormone for immuno-suppression (at a dose of > 10 mg/ day of prednisone or equivalent) within 2 weeks before the first dose of the study drug; Inhaled or topical steroids and corticosteroid replacement at doses > 10 mg/ day of prednisone or equivalent were allowed in the absence of active autoimmune disease; (c) live attenuated vaccine within 4 weeks before the first dose of study drug; (d) major surgery or severe trauma within 4 weeks before the first dose of study drug.Human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) active infection, or known HIV seropositivity; including HBV or HCV surface antigen positive (RNA).Uncontrolled cardiac symptoms or diseases, including but not limited to (1) heart failure above NYHA class II, (2) unstable angina, (3) myocardial infarction within 1 year, and (4) clinically important significant supraventricular or ventricular arrhythmias without or poorly controlled after the clinical intervention.Severe infection (CTCAE > 2) occurring within 4 weeks before the first dose of the study drug, such as severe pneumonia requiring hospitalization, bacteremia, and infectious complications; patients using prophylactic antibiotics were excluded if there was active pulmonary inflammation on chest imaging at baseline, if there were signs and symptoms of infection within 14 days before the first dose of the study drug, or if treatment with oral or intravenous antibiotics was needed.Participation in other drug clinical studies within 4 weeks before randomization.Patients with interstitial pneumonia or interstitial lung disease, or previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy; or other subjects with pulmonary fibrosis, organized pneumonia (such as bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that could interfere with the assessment and treatment of immune-related pulmonary toxicity; subjects with active pneumonia or severe lung function damage revealed by CT during screening; patients with active pulmonary tuberculosis.Patients with any active autoimmune disease or history of autoimmune disease and possible recurrence [including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (patients who can be controlled only by hormone replacement therapy can be enrolled); patients with skin diseases that do not require systemic treatment, such as leukoplakia, psoriasis, alopecia; patients with type I diabetes that can be controlled by insulin treatment; patients with a history of asthma, but those with childhood asthma not requiring intervention can be enrolled; asthma patients who needed bronchodilators for intervention; patients who had previously received an anti-PD-1, PD-L1 or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.Other malignancies that had been diagnosed within 5 years before the first dose of a study drug were considered unless cancers with a low risk of metastasis or death (5-year survival rate, > 90%), such as adequately treated basal-cell or squamous-cell skin cancer or carcinoma in situ of the cervix, were considered.Pregnant or lactating women.The investigators determined that there were other factors that might lead to the forced discontinuation of the study, such as family or social factors, other serious medical conditions (including mental illness) requiring cotreatment, alcohol abuse, and substance abuse, as well as factors that could affect the safety or compliance of the subjects.